To investigate a potential link between JNK activity and therapy resistance in clinical samples, we examined gene expression data sets from breast cancer patients who had undergone neoadjuvant anthracycline chemotherapy treatment (Li et al, 2010). This evidence concerns the gene MAPK8 and breast carcinoma.